{"title":"美国糖尿病协会-第70届科学会议-新疗法的研究:第1部分。","authors":"Gary Croasdell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucagon-like peptide-1 (GLP-1) agonist taspoglutide (Roche Holding AG/Teijin Ltd/ Chugai Pharmaceutical Co Ltd), the GLP-1 analog SKL-18287 (Sanwa Kagaku Kenkyusho Co Ltd), the sodium glucose transporter-2 (SGLT2) inhibitor ASP-1941 (Astellas Pharma Inc/Kotobuki Pharmaceutical Co Ltd), the dual SGLT2/1 inhibitor LX-4211 (Lexicon Pharmaceuticals Inc), and the selective PPARgamma modulator INT-131 (InteKrin Therapeutics Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"595-7"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.\",\"authors\":\"Gary Croasdell\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucagon-like peptide-1 (GLP-1) agonist taspoglutide (Roche Holding AG/Teijin Ltd/ Chugai Pharmaceutical Co Ltd), the GLP-1 analog SKL-18287 (Sanwa Kagaku Kenkyusho Co Ltd), the sodium glucose transporter-2 (SGLT2) inhibitor ASP-1941 (Astellas Pharma Inc/Kotobuki Pharmaceutical Co Ltd), the dual SGLT2/1 inhibitor LX-4211 (Lexicon Pharmaceuticals Inc), and the selective PPARgamma modulator INT-131 (InteKrin Therapeutics Inc).</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 9\",\"pages\":\"595-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
美国糖尿病协会第70届科学会议在美国佛罗里达州奥兰多举行，主题包括糖尿病研究领域的新治疗发展。本会议报告重点介绍了使用新型药物进行的新研究。讨论的研究药物包括胰高血糖素样肽-1 (GLP-1)激动剂taspoglutide (Roche Holding AG/Teijin Ltd/ Chugai Pharmaceutical Co Ltd)， GLP-1类似物SKL-18287 (Sanwa Kagaku Kenkyusho Co Ltd)，钠葡萄糖转运体-2 (SGLT2)抑制剂ASP-1941 (Astellas Pharma Inc/Kotobuki Pharmaceutical Co Ltd)，双SGLT2/1抑制剂LX-4211 (Lexicon Pharmaceuticals Inc)和选择性PPARgamma调节剂INT-131 (InteKrin Therapeutics Inc)。
American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.
The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucagon-like peptide-1 (GLP-1) agonist taspoglutide (Roche Holding AG/Teijin Ltd/ Chugai Pharmaceutical Co Ltd), the GLP-1 analog SKL-18287 (Sanwa Kagaku Kenkyusho Co Ltd), the sodium glucose transporter-2 (SGLT2) inhibitor ASP-1941 (Astellas Pharma Inc/Kotobuki Pharmaceutical Co Ltd), the dual SGLT2/1 inhibitor LX-4211 (Lexicon Pharmaceuticals Inc), and the selective PPARgamma modulator INT-131 (InteKrin Therapeutics Inc).
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
